Sanofi to Post Q2 2024 Earnings of $0.90 Per Share, Leerink Partnrs Forecasts (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs cut their Q2 2024 earnings per share (EPS) estimates for Sanofi in a report issued on Thursday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $0.90 for the quarter, down from their previous forecast of $0.91. The consensus estimate for Sanofi’s current full-year earnings is $4.09 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.87 EPS, FY2026 earnings at $4.95 EPS and FY2027 earnings at $5.47 EPS.

Other analysts also recently issued research reports about the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley assumed coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Stock Down 0.5 %

NASDAQ SNY opened at $49.13 on Monday. The stock’s 50-day moving average price is $47.71 and its 200-day moving average price is $48.32. The company has a market capitalization of $124.28 billion, a P/E ratio of 24.69, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61. Sanofi has a 52 week low of $42.63 and a 52 week high of $56.26. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is presently 69.35%.

Institutional Investors Weigh In On Sanofi

Several hedge funds and other institutional investors have recently made changes to their positions in SNY. Rise Advisors LLC boosted its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new stake in Sanofi in the 4th quarter valued at approximately $27,000. Venturi Wealth Management LLC boosted its holdings in Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in Sanofi in the 4th quarter valued at approximately $28,000. Finally, Register Financial Advisors LLC purchased a new stake in Sanofi in the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.